Secu-Kinamab in Giant Cellaritis

Only 1.7% had paradoxical reactions occurring in a median of 12 months after the TNF inhibitor, as was reported previously with other paradoxical reactions. 73% however, were able to favorably switch to another TNF inhibitor. Another interesting report, but this was only a small study of 15 cases, was B-limamab in adults with inflammatory myositis. Secu-Kinamab was superior to placebo in treating patients who had refractory disease despite steroids with active giant cell arthritis.